SONAR
29.5.2024 15:01:32 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced that SonarQube is now available on Google Cloud Marketplace, enabling organizations to accelerate DevOps transformations in the cloud, modernize software development workflows, and deliver higher-quality, secure applications. As companies adopt AI code generation tools, SonarQube ensures that no matter where or how code is developed, it leads to secure, reliable, and maintainable software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529150627/en/
SonarQube is now available on Google Cloud Marketplace. (Photo: Business Wire)
SonarQube’s availability on Google Cloud Marketplace streamlines the process for developers to identify and address potential issues in code early on in the software development lifecycle (SDLC), whether code is human-developed or AI-generated. Developers can now quickly set up SonarQube in their Google Cloud environment to analyze their code quality with simplified billing and scalability that fit their specific needs and budget. Organizations are empowered to accelerate their DevOps transformation initiatives while minimizing risks and ensuring long-term success.
“Bringing SonarQube to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the solution on Google Cloud's trusted, global infrastructure," said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud. “Sonar can now securely scale and support customers on their digital transformation journeys.”
Google Cloud Marketplace lets users quickly deploy functional software packages that run on Google Cloud's infrastructure. Google Cloud Marketplace allows customers to easily start up a familiar software package with services like Compute Engine or Cloud Storage, with no manual configuration required.
Over the last 15 years, Sonar has analyzed more than half a trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. Sonar evaluates code for quality and security issues at two points - in the IDE with SonarLint, and in the Continuous Integration (CI) pipeline, with SonarQube. Sonar’s offering is built on the principles of Clean Code, which is the belief that when code is consistent, intentional, adaptable, and responsible – meaning it is easy to understand and change, operates smoothly at runtime, and contains no technical debt – it results in software that is maintainable, reliable, of quality, and secure.
“Code is one of the most valuable assets in a digital economy. As companies adopt AI and move to the cloud, we want them to continue having seamless access to Sonar’s Clean Code solutions as part of their DevOps environment in the cloud,” said Harry Wang, VP of Strategic Partnerships & Head of Product Marketing at Sonar. “SonarQube availability on Google Cloud Marketplace means that organizations can easily combine Google’s AI capabilities with the familiar Clean Code solution that they trust, to evolve and accelerate software development safely and responsibly.”
SonarQube is an essential tool in the current DevOps toolchain as it reduces issues before they reach production, reduces rollbacks and rework, increases developer velocity, and increases DevOps efficiency and agility. By preventing new issues from entering into production, software becomes easier to maintain and businesses become more competitive, as new features are faster to add.
Key benefits of its availability on Google Cloud Marketplace include:
- Faster Setup: Get up and running with SonarQube quickly and easily, eliminating the need for complex manual installations.
- Seamless Integration: Developers can incorporate SonarQube into their Google Cloud environment with the ease of container deployment on Google Kubernetes Engine (GKE).
- Scalability: Usage of SonarQube can easily scale with Google Cloud’s infrastructure to match evolving needs, no matter the size of the organization or software project.
- Simplified Billing and Cost Effectiveness: Companies can consolidate the purchase of SonarQube with the rest of their cloud spending to achieve better discounts on Google Cloud and reduce administrative overhead.
To learn more about SonarQube, visit here. SonarQube is generally available now on Google Cloud Marketplace.
About Sonar
Sonar is a leading maker of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.
To learn more about Sonar, please visit https://www.sonarsource.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529150627/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom